Newsroom
Press Releases
mQOL to present observational study interim results at International Myeloma Society meeting
September 19, 2025
SAN JOSE, Calif. - Sept. 19, 2025 - PRLog -- mQOL, a pioneering health technology company focused on enhancing measurable symptom monitoring, quality of life and medication adherence through smart data and digital solutions, announced its research abstract has been accepted for poster presentation at IMS in Toronto, Canada (September 17-20, 2025). The abstract, "mQOL, a text-based Remote Therapeutic Monitoring (RTM) Platform for Symptom (Sx) and Quality of Life (QoL) Tracking in Multiple Myeloma (MM): Interim Results from a Prospective Observational Study," will also be published as a special supplement to the Clinical Lymphoma, Myeloma, & Leukemia Journal.
"The ability to closely monitor patients with multiple myeloma in real time offers the potential to significantly enhance quality of life while improving overall survival outcomes. mQOL establishes an important advancement in embedding patient-reported symptom and quality-of-life (QoL) tracking into the standard of care for multiple myeloma management," said Dr. Blake Morrison, SVP of Medical Affairs and Development at mQOL. "This application can be utilized in other oncologic malignancies and conditions outside of cancer."
The abstract presents interim results from a prospective observational study MQ-mQOL-001. Enrollment included 58 multiple myeloma patients from a single cancer center in three cohorts: Newly Diagnosed Multiple Myeloma (NDMM), Relapsed / Refractory Multiple Myeloma (RRMM) and Maintenance Therapy (Maint), with the study occurring March 27 - May 12, 2025. Study completion occurred in August 2025.
This proof-of-concept study demonstrated that mQOL's HIPAA-compliant text-based platform significantly improved symptom and quality of life tracking in multiple myeloma patients, with nearly 90% patient completion rate and identification of hundreds of potentially actionable clinical events.
"The high number of potential actionable events flagged identifies clinically significant problems that clinicians can immediately address," said Dr. James Berenson, President & Medical Director of the Berenson Cancer Center and principal investigator of the mQOL-sponsored study.
mQOL transforms cancer care through continuous patient insights, placing QoL at the core of care. With a fast, simple patient setup, and no apps to download, mQOL helps address a significant gap in real-time patient monitoring between clinical visits. By frequently capturing data directly from patients, mQOL helps identify key trends and supports critical clinical insights that may otherwise be missed.
"When patients are empowered to share their symptoms and quality of life in real time, care becomes not just more effective, it becomes more human," said mQOL Founder and CEO Frank Pezzullo. "You can't measure what you don't track."
Full data analysis can be found on the mQOL website at mqol.com/IMS2025mQOL and Berenson Cancer Center Partner on Groundbreaking Observational Study to Enhance Oncology Care
March 27, 2025
mQOL, a pioneering digital health company, is pursuing the launch of its specialized platform designed to capture high-fidelity Patient-Reported Outcomes (PROs) including symptom status and Quality of Life (QoL) data in real-time. mQOL has validated and transformed the communication mechanisms of how patient reported outcomes are best captured and are excited to launch the platform in Oncology. With an initial focus and deep commitment to serve the multiple myeloma community, we are thrilled to announce the launch of mQOL’s prospective observational study in partnership with the highly renown Berenson Cancer Center in West Hollywood, CA. This pioneering initiative is set to evaluate the accessibility, completion rate, time burden, and clinical utility of capturing real-time symptom and Quality of Life (QoL) data for patients with multiple myeloma.
mQOL is dedicated to enhancing cancer care by empowering patients to direct PROACTIVE, timely, accurate, and actionable patient insights to healthcare providers, enabling the potential for early intervention and improved outcomes. Through our HIPAA-compliant SMS-based digital remote monitoring platform, mQOL aims to bridge critical gaps in oncology care by enabling real-time, patient-reported outcomes (PROs) that empower both patients and healthcare providers. By leveraging a seamless, app-free approach, this study will assess how consistent, high-fidelity symptom tracking can enhance patient engagement and optimize clinical decision-making. The mQOL platform is designed to handle the complexities, empowering physicians with more data, while giving patients a voice in their treatment journey.
Key Highlights of the Study:
✅ Single-center feasibility study focused on multiple myeloma patients✅ Principal Investigator, Dr. James Berenson, Principal Investigator at Berenson Cancer Center
✅ Target enrollment of 50 myeloma patients spanning newly diagnosed, relapsed/refractory, and maintenance therapy cohorts
✅ 90-day evaluation period assessing patient engagement and clinical impact in a concentrated manner
✅ Real-time monitoring and reporting to inform timely interventions determined by the study site
This study marks an important step in transforming oncology care, ensuring that Quality of Life is at the core of cancer treatment.
We look forward to sharing insights as the study progresses!
📍 Learn more about mQOL at www.mqol.com
#mQOL #OncologyCare #PatientCentered #DigitalHealth #MultipleMyeloma #RealWorldData #ClinicalResearch #PROs #QoL
Events & Presentations
Press Release 1
Change the text and add your own content, including any information that is relevant to share. Then customize the font, size and scale to make it your own.
Press Release 1
Change the text and add your own content, including any information that is relevant to share. Then customize the font, size and scale to make it your own.
Press Release 1
Change the text and add your own content, including any information that is relevant to share. Then customize the font, size and scale to make it your own.
Corporate Governance
Press Release 1
Change the text and add your own content, including any information that is relevant to share. Then customize the font, size and scale to make it your own.